ロード中...
Targeted IV busulfan and fludarabine followed by post-allogeneic hematopoietic cell transplantation rituximab demonstrate encouraging activity in CD20+ lymphoid malignancies without increased risk of infectious complications
We examined pharmacokinetic-targeted IV busulfan (75–170 mg/m(2), with target AUC of 3500–6000 μmol min) and fludarabine (40 mg/m(2)) × 4 days with rituximab (t-IV Bu/Flu + rituximab) 375 mg/m(2) on days +1 and +8 followed by allogeneic hematopoietic cell transplantation in 19 patients (median age 5...
保存先:
| 出版年: | Int J Hematol |
|---|---|
| 主要な著者: | , , , , , , , , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
2011
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5718616/ https://ncbi.nlm.nih.gov/pubmed/21246311 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s12185-010-0747-x |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|